Form 4: Cullinan Therapeutics Director Mary Thistle Acquires 25,743 Stock Options

Director Mary Thistle acquired 25,743 stock options in Cullinan Therapeutics, Inc. on August 8, 2024.

Summary

• On August 8, 2024, Mary Thistle, a director of Cullinan Therapeutics, Inc., acquired 25,743 stock options.
• The exercise price of these options is $16.38.
• The options vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent upon continued service as a director.
• The options expire on August 8, 2034.
• Following the transaction, Mary Thistle directly owns 25,743 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction by a company director. The acquisition of stock options can be seen as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the director's stock option acquisition as a positive sign of confidence in the company's future.

Key Dates